• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Maxim Group initiated coverage on Assertio Therapeutics with a new price target

    7/26/24 7:49:44 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASRT alert in real time by email
    Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00
    Get the next $ASRT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASRT

    DatePrice TargetRatingAnalyst
    7/26/2024$3.00Buy
    Maxim Group
    7/3/2024$4.00Buy
    H.C. Wainwright
    11/7/2022$7.00Buy
    Lake Street
    More analyst ratings

    $ASRT
    SEC Filings

    See more
    • SEC Form DEF 14A filed by Assertio Holdings Inc.

      DEF 14A - Assertio Holdings, Inc. (0001808665) (Filer)

      4/8/25 4:40:37 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Assertio Holdings Inc.

      PRE 14A - Assertio Holdings, Inc. (0001808665) (Filer)

      3/25/25 5:24:21 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Assertio Holdings Inc.

      10-K - Assertio Holdings, Inc. (0001808665) (Filer)

      3/12/25 5:14:59 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, General Counsel Schlessinger Sam converted options into 17,150 shares and covered exercise/tax liability with 7,656 shares, increasing direct ownership by 7% to 153,889 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      2/25/25 6:03:18 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Schwichtenberg Paul converted options into 17,150 shares and covered exercise/tax liability with 8,505 shares, increasing direct ownership by 6% to 146,345 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      2/25/25 6:02:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP and CFO Patel Ajay converted options into 17,150 shares and covered exercise/tax liability with 8,505 shares, increasing direct ownership by 5% to 175,675 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      2/25/25 6:00:12 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Leadership Updates

    Live Leadership Updates

    See more
    • Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors

      LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. "Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to our board," said Heather Mason, Chair of Assertio. "His successful new product and indication launches have b

      12/17/24 8:30:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Holdings, Inc. Appoints Paul Schwichtenberg to New CTO Role, Mary Pietryga as CCO

      LAKE FOREST, Ill., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced today the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company's Chief Commercial Officer and was previously CFO. "As CTO, Paul will be future looking, working closely with me, to identify synergies, innovative strategies, and new revenue streams to best position the company for future growth," said Brendan O'Grady, Chief Executi

      12/12/24 8:00:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

      CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

      12/6/24 7:00:00 AM ET
      $ASRT
      $BEAM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mason Heather L bought $60,000 worth of shares (75,000 units at $0.80), increasing direct ownership by 35% to 287,650 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      11/19/24 9:02:18 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO O'Grady Brendan P. bought $9,950 worth of shares (11,706 units at $0.85) (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      11/15/24 2:43:25 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Vacirca Jeff L bought $11,100 worth of shares (10,000 units at $1.11), increasing direct ownership by 7% to 151,159 units (SEC Form 4)

      4 - Assertio Holdings, Inc. (0001808665) (Issuer)

      6/12/24 6:00:09 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

      LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

      5/5/25 8:15:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025

      LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present at the iAccess Alpha Best Ideas Spring Investment Conference taking place virtually March 25-26, 2025. The Company will present at 1:30 pm Eastern Time on Tuesday, March 25, 2025. To join the presentation, please visit the webcast available online at https://investor.assertiotx.com/. Additionally, investors participating in the conference can request 1x1 meetings to take place on March 26, 2025 via their conference representative or through Assertio investor relations at [email protected]. T

      3/20/25 9:10:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. Said Brendan O'Grady, Chief Executive Officer, "In line with our strategy for Assertio's long-term growth, 2024 was a year of stabilization as we transitioned to Rolvedon as our primary a

      3/12/25 4:05:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Financials

    Live finance-specific insights

    See more
    • Assertio Holdings, Inc. to Report First Quarter 2025 Financial Results on May 12, 2025

      LAKE FOREST, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release first quarter 2025 financial results on Monday, May 12, 2025, after the market close. Additionally, Assertio's management will host a live webcast conference call at 4:30 p.m. Eastern Time to discuss the financial results and update the Company's 2025 strategic plans. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate tim

      5/5/25 8:15:00 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Reports Fourth Quarter and Full Year 2024 Financial Results

      Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Operations of $26.4 Million, Cash and Investments Increases to $100.1 Million LAKE FOREST, Ill., March 12, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today reported financial results for the fourth quarter and full year ended December 31, 2024. Said Brendan O'Grady, Chief Executive Officer, "In line with our strategy for Assertio's long-term growth, 2024 was a year of stabilization as we transitioned to Rolvedon as our primary a

      3/12/25 4:05:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025

      LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2024 financial results on Wednesday, March 12, 2025, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for a

      3/5/25 4:05:00 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Assertio Therapeutics with a new price target

      Maxim Group initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $3.00

      7/26/24 7:49:44 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Assertio Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $4.00

      7/3/24 7:25:55 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Assertio Therapeutics with a new price target

      Lake Street initiated coverage of Assertio Therapeutics with a rating of Buy and set a new price target of $7.00

      11/7/22 9:24:08 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

      SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

      11/14/24 3:52:50 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

      SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

      11/12/24 1:34:28 PM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Assertio Holdings Inc.

      SC 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)

      11/4/24 11:29:13 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

      Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

      6/10/24 1:20:50 AM ET
      $ASRT
      Biotechnology: Pharmaceutical Preparations
      Health Care